Vor has signed a licensing agreement to access MaxCyte's Flow Electroporation technology and ExPERT family of instruments.
They will be deployed to deliver gene editing machinery into hematopoietic stem cells to remove biologically redundant proteins that are also expressed on blood cancer cells.
Hematopoietic stem cells create white and red blood cells as well as platelets and are found in bone marrow.
Vor has pioneered a process that creates engineered hematopoietic stem cells. Its lead candidate is VOR 33 for the treatment of acute myeloid leukemia.
No financial details of the licensing agreement were revealed; however, Maxcyte said it will receive development and approval milestones and “sales-based payments in addition to other licensing fees”.